NSE: INFY | BSE: 500209

Mid-range Performer

Download real time

1499.40 29.80 (2.03%)

25.27% Fall from 52W High

4.6M NSE+BSE Volume

NSE 01 Sep, 2025 3:31 PM (IST)

622,909.6

Market Cap

Market Runner Up

1.1

Beta 1Year

High Volatility

Infosys Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INFY, BSE:500209 Infosys Ltd.

Infosys Ltd.

18 Apr 2025

1499.40

2.03%

Infosys (HOLD): A weak FY26 revenue guidance

Hold: Infosys Ltd.

Target

BOB Capital Markets Ltd.

Both 4QFY25 and FY26 guidance were weaker than expected. The ~25% CYTD stock decline possibly prices some of that in

Infosys Ltd. is trading above its 30 day SMA of 1492.1

Infosys Ltd.

17 Apr 2025

1499.40

2.03%

Poor 4Q but commentary springs a surprise

Neutral: Infosys Ltd.

Recommendation Target

Motilal Oswal

Infosys (INFO) reported 4QFY25 revenue of USD4.7b, down 3.5% QoQ CC/up 4.8% YoY CC vs. our estimate of 1.0% QoQ CC decline. For full year, revenue stood at USD19.2b, up 4.2% YoY CC. EBIT margins stood at 21% vs. our estimates of 20.6%. EBIT declined 3.8% QoQ/up 12.5% YoY to INR85b (est. INR87b).

Number of FII/FPI investors decreased from 1775 to 1705 in Jun 2025 qtr

Infosys Ltd.

17 Apr 2025

1499.40

2.03%

Weak Q4, macro headwinds drive soft FY26 outlook

Buy: Infosys Ltd.

Target

Sharekhan

Reported revenues stood at $4,730 million, down 3.5% q-o-q/up 4.8% y-o-y in CC terms, missing our estimate of $4,842 million owing to lower third-party costs and revenue, and seasonality. Revenue in rupee terms stood at Rs 40,925 crore down 2% q-o-q/up 7.9% y-o-y.

Infosys Ltd. is trading above its 30 day SMA of 1492.1

Infosys Ltd.

17 Apr 2025

1499.40

2.03%

Infosys: Q4FY25 Result Review

Hold: Infosys Ltd.

Target

IDBI Capital

Number of FII/FPI investors decreased from 1775 to 1705 in Jun 2025 qtr

Infosys Ltd.

30 Jan 2025

1499.40

2.03%

INFOSYS LIMITED

Hold: Infosys Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors decreased from 1775 to 1705 in Jun 2025 qtr

Infosys Ltd.

17 Jan 2025

1499.40

2.03%

Pass-through revenue aids growth; implied Q4 guidance disappoints

Buy: Infosys Ltd.

Target

Emkay

Infosys reported better than expected revenue growth in Q3. Revenue grew 1.7% QoQ CC, partly aided by increase in pass-through revenue and incremental contribution (20bps) from the in-tech acquisition. EBITM expanded by 20bps to 21.3%, in line with expectation.

Number of FII/FPI investors decreased from 1775 to 1705 in Jun 2025 qtr

Infosys Ltd.

17 Jan 2025

1499.40

2.03%

Infosys (HOLD): Broadening of discretionary spend

Hold: Infosys Ltd.

Target

BOB Capital Markets Ltd.

3QFY25 beats our estimates. European BFS and US Retail & CPG discretionary spends pick up. Higher than usual pass through impacts

Infosys Ltd. is trading below its 50 day SMA of 1538.5

Infosys Ltd.

17 Jan 2025

1499.40

2.03%

Guidance lifts, but commentary cautious

Buy: Infosys Ltd.

Motilal Oswal

Infosys (INFO) reported 3QFY25 revenue of USD4.9b, growth of 1.7% QoQ/6.1% YoY CC vs. our estimate of 1.0% QoQ CC. EBIT margins stood at 21.3% vs. our estimates of 20.8%. EBIT grew 3.0% QoQ/11.9% YoY to INR89b (est. INR86b). PAT came in at INR68b, up 4.6% QoQ/11.5% YoY, in line with our estimate of INR68b.

Infosys Ltd. is trading below its 50 day SMA of 1538.5

Infosys Ltd.

17 Jan 2025

1499.40

2.03%

Infosys: Q3FY25 Result Review

Hold: Infosys Ltd.

Target

IDBI Capital

Infosys Ltd. is trading below its 50 day SMA of 1538.5

Infosys Ltd.

16 Jan 2025

1499.40

2.03%

Good quarter, expecting softer Q4

Buy: Infosys Ltd.

Sharekhan

Reported revenue stood at $4,939 million, up 1.7% q-o-q in constant currency (CC) terms, beating our estimate of $4,876 million. EBIT margins improved ~20 bps q-o-q to 21.3 %, beating our estimates. Company closed 17 large deals with TCV of $2.5 billion, up ~3% q-o-q/down 27% y-o-y.

Infosys Ltd. has an average target of 1702.64 from 11 brokers.

Is Infosys Ltd. worth buying?

4123 Votes:

Buy 75.92%

Sell 11.4%

Hold 12.68%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf